|
The Depression in Alzheimer's Disease Study (DIADS) Clinical Trials References presented on Clinical Trials Search is not intended to be a substitute for proven healthcare advice, trips or professional assistance by using a real medical. We aren't mDs. Always confer with your physician about The Depression in Alzheimer's Disease Study (DIADS) conditions. Clinical Trials Search.org is a website devoted to listing clinical research studies in human subjects. The Depression in Alzheimer's Disease Study (DIADS) Clinical research trials and The Depression in Alzheimer's Disease Study (DIADS) medical trials take place in hundreds of localities across the U.S.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectualness of new does drugs. The purpose of the studies / projects is to solve specific human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to discover treatments for all sorts of conditions, such as The Depression in Alzheimer's Disease Study (DIADS). The Depression in Alzheimer's Disease Study (DIADS) Clinical Trials and other clinical trials permit volunteers to access healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for without cost, and every now and again they are compensated for their time. Sometimes there is a cost for a The Depression in Alzheimer's Disease Study (DIADS) clinical trial. Subjects often receive the most expert healthcare possible for their The Depression in Alzheimer's Disease Study (DIADS) condition. Risks are a reality, nevertheless, and could include additional or frequent dr. calls, healthcare dangers (perhaps life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with stern guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > The Depression in Alzheimer's Disease Study (DIADS)  The Depression in Alzheimer's Disease Study (DIADS)
The Depression in Alzheimer's Disease Study (DIADS)
For Condition: Depression,Alzheimer Disease
Status: No longer recruiting
Sponsor(s): National Institute of Mental Health (NIMH) ,
Synopsis: Major depression afflicts approximately 25 percent of patients with AD. Depression in AD patients leads to mental suffering, behavioral disturbance (such as aggression), poor cognition, poor self-care, caregiver depression, caregiver burden, and early entry into the nursing home. Since major depression is treatable, this additional disability may be avoidable. The use of antidepressants to treat major depression in AD is supported by two studies, although a third does not show a benefit for antidepressants over placebo. Also, the safety of antidepressant treatment in depressed AD patients is poorly studied. A conclusive study showing that depression reduction in AD can be accomplished safely with antidepressant medications, and that depression reduction is associated with improvements in activities of daily living, non-mood behavioral disturbances, caregiver burden, and caregiver depression would have major clinical and cost implications for the care of the AD patient. This study is a 13-week, double blind, flexible dose, placebo controlled trial of sertraline in the treatment of outpatients with AD and co-morbid major depression. The hypothesis is that antidepressant treatment is superior to placebo in improving mood, in improving cognition, in reducing physical dependency, in reducing caregiver depression, and in reducing caregiver burden. It is also hypothesized that the degree of depression reduction is correlated with these improvements. It is further hypothesized that the safety profile of sertraline when compared to placebo is acceptable, especially with regard to risk of falls, sleep disturbance, and delirium. One hundred community residing outpatients with probable AD who also meet DSM-IV criteria for major depressive episode will be recruited into the study. They will be randomized to sertraline or placebo and followed through weekly telephone contact by an experienced clinical trials team. Outcomes will be assessed every 3 weeks, for a total of four followup data points. Scales assessing the following domains will be used: depression, cognition, behavioral disturbance, physical dependency, delirium, falls, sleep, other side effects, caregiver depression, caregiver burden, caregiver functioning, and caregiver health.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Inclusion: - Diagnosis of Probable Alzheimer's disease (AD) by NINCDS/ADRDA criteria (McKann et al., 1984), with a MMSE score greater than 10 - Diagnosis of current major depressive episode (MD), by DSM-IV, based on the SCID-IV examination - Patients will be included even if they have a pre-AD history of unipolar depression - Patients who currently are being treated with antidepressants but continue to meet criteria for MD (i.e., have not responded to the medications) and who are willing to discontinue the other medication and enter the study also will be included - Currently residing in the community (own home,family member's home, or small group home) and agreeing to 13 weeks of followup in the study - Stable medical history and general health, in the opinion of the study psychiatrist - A caregiver who knows the patient well (spends at least 10 hours per week with him or her), and who is in reasonably good health, agrees to participate as well - Participant and his/her legal representative provide informed consent Exclusion: - Use of sertraline is contraindicated, based on the Food and Drug Administration package insert for sertraline - Patient has a lifetime diagnosis of schizophrenia, bipolar disorder, or pre-AD anxiety disorder, as determined by the SCID - Patient has a current substance use disorder, as determined by the SCID - Patient is acutely suicidal or requires inpatient psychiatric hospitalization, as determined by the study psychiatrist - No psychotropic medicine dose changes, including cholinesterase inhibitors, after study entry - May enter with any drug except another antidepressant.
Total Enrollment:
Location and Contact Information:
Johns Hopkins University
Baltimore, Maryland, 21224
United States
Additional Information:
Study ID Numbers: IA0010;
Study Start Date:
Record last reviewed: June 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00009191
Other Depression Studies:
1. Anxiety and Vagal Control of the Heart in Coronary Disease
2. Therapy for Depression with Co-occurring Panic or Anxiety Symptoms
3. The Effects of Hormone Withdrawal on Mood Symptoms in Women with Perimenopausal Depression
4. Genetics of Recurrent Early-Onset Depression
5. Brain Imaging in Depression
Related Studies:
Other Depression Clinical Trials
Other Maryland Clinical Trials
Other Baltimore Clinical Trials
The Depression in Alzheimer's Disease Study (DIADS)
|
|
|
|
|
|
|
|
